Thomas Meier
Founder at SANTHERA PHARMACEUTICALS HOLDING AG
Net worth: 141 664 $ as of 2024-04-29
Thomas Meier active positions
| Companies | Position | Start | End |
|---|---|---|---|
| SANTHERA PHARMACEUTICALS HOLDING AG | Chairman | 2022-06-29 | - |
| Founder | 2004-09-06 | - | |
| Director/Board Member | 2017-04-03 | 2022-06-29 | |
| Chief Executive Officer | 2011-10-10 | 2019-11-30 | |
| Investor Relations Contact | - | - | |
| Public Communications Contact | - | - | |
| ONCONETIX, INC. | Director/Board Member | 2024-02-05 | - |
Novaremed AG
 Novaremed AG Pharmaceuticals: MajorHealth Technology Novaremed AG operates as a pharmaceutical company. It develops NEB74S, a molecule for the treatment of chronic pain. The company was founded by Eliahu Kaplan in 2008 and is headquartered in Petah Tikva, Israel. | Director/Board Member | 2020-04-30 | - |
Viopas Venture Consulting GmbH
 Viopas Venture Consulting GmbH Investment ManagersFinance Viopas Venture Consulting GmbH (Viopas Venture Consulting) is a venture capital firm founded in 2016 by Simon Jules Nebel. The firm is headquartered in Zürich, Switzerland. | Corporate Officer/Principal | - | - |
Visgenx, Inc.
 Visgenx, Inc. BiotechnologyHealth Technology Visgenx, Inc. engages in the development of therapeutics to protect against the loss of sight from retinal disorders. Its product pipeline includes Intravitreal Decitabine and gene therapy. The company was founded by Santosh J. Vetticaden and Robert Martin Emanuele and is headquartered in San Diego, CA. | Director/Board Member | 2021-12-31 | - |
Career history of Thomas Meier
Former positions of Thomas Meier
| Companies | Position | Start | End |
|---|---|---|---|
PharmaBiome AG
 PharmaBiome AG Miscellaneous Commercial ServicesCommercial Services PharmaBiome AG specializes in isolation, characterization, and technology of novel intestinal microbes. It develops and produces microbiome therapies to treat intestinal diseases. The company was founded by Tomas de Wouters and is headquartered in Zurich, Switzerland. | Chairman | 2020-06-30 | 2020-12-31 |
| MyoContract AG | Chief Executive Officer | 1999-12-31 | 2003-12-31 |
| Founder | 1999-12-31 | 2003-12-31 |
Training of Thomas Meier
| University of Basel | Doctorate Degree |
Statistics
International
| Switzerland | 7 |
| United States | 3 |
Operational
| Director/Board Member | 4 |
| Chairman | 3 |
| Founder | 3 |
Sectoral
| Health Technology | 6 |
| Consumer Services | 2 |
| Commercial Services | 2 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
| Listed companies | 2 |
|---|---|
| SANTHERA PHARMACEUTICALS HOLDING AG | Health Technology |
| ONCONETIX, INC. | Health Technology |
| Private companies | 5 |
|---|---|
| MyoContract AG | Health Technology |
Novaremed AG
Novaremed AG Pharmaceuticals: MajorHealth Technology Novaremed AG operates as a pharmaceutical company. It develops NEB74S, a molecule for the treatment of chronic pain. The company was founded by Eliahu Kaplan in 2008 and is headquartered in Petah Tikva, Israel. | Health Technology |
PharmaBiome AG
PharmaBiome AG Miscellaneous Commercial ServicesCommercial Services PharmaBiome AG specializes in isolation, characterization, and technology of novel intestinal microbes. It develops and produces microbiome therapies to treat intestinal diseases. The company was founded by Tomas de Wouters and is headquartered in Zurich, Switzerland. | Commercial Services |
Viopas Venture Consulting GmbH
Viopas Venture Consulting GmbH Investment ManagersFinance Viopas Venture Consulting GmbH (Viopas Venture Consulting) is a venture capital firm founded in 2016 by Simon Jules Nebel. The firm is headquartered in Zürich, Switzerland. | Finance |
Visgenx, Inc.
Visgenx, Inc. BiotechnologyHealth Technology Visgenx, Inc. engages in the development of therapeutics to protect against the loss of sight from retinal disorders. Its product pipeline includes Intravitreal Decitabine and gene therapy. The company was founded by Santosh J. Vetticaden and Robert Martin Emanuele and is headquartered in San Diego, CA. | Health Technology |
- Stock Market
- Insiders
- Thomas Meier
- Experience
